Stephens Consulting’s Edgewise Therapeutics EWTX Stock Holding History

Stephens Consulting’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$660	–	1454
2025 Q1	$660	Buy	+30	New	+$787	﹤0.01%	857

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stephens Consulting's EWTX Position: Q2 2025 in Review

Stephens Consulting sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 30 shares — an estimated $660 sold.

Stephens Consulting first reported a position in EWTX in Q1 2025 and held it in 1 quarter. The position peaked at $660 in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

Stephens Consulting reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 30 Edgewise Therapeutics shares in Q2 2025, an estimated $660.
Stephens Consulting first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Edgewise Therapeutics position peaked at $660 in Q1 2025.
178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.